{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:11:18Z","timestamp":1780373478031,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Botulinum neurotoxin (BoNT) shows high lethality and toxicity, marking it as an important biological threat. The only effective post-exposure therapy is botulinum antitoxin; however, such products have great potential for improvement. To prevent or treat BoNT, monoclonal antibodies (mAbs) are promising agents. Herein, we aimed to construct a bispecific antibody (termed LUZ-A1-A3) based on the anti-BoNT\/A human monoclonal antibodies (HMAb) A1 and A3. LUZ-A1-A3 binds to the Hc and L-HN domains of BoNT\/A, displaying potent neutralization activity against BoNT\/A (124\u2009\u00d7\u2009higher than that of HMAb A1 or HMAb A3 alone and 15\u2009\u00d7\u2009higher than that of the A1\u2009+\u2009A3 combination). LUZ-A1-A3 provided effective protection against BoNT\/A in an in vivo mouse model. Mice were protected from infection with 500\u2009\u00d7\u2009LD<jats:sub>50<\/jats:sub> of BoNT\/A by LUZ-A1-A3 from up to 7\u00a0days before intraperitoneal administration of BoNT\/A. We also demonstrated the effective therapeutic capacity of LUZ-A1-A3 against BoNT\/A in a mouse model. LUZ-A1-A3 (5\u00a0\u03bcg\/mouse) neutralized 20\u2009\u00d7\u2009LD<jats:sub>50<\/jats:sub> of BoNT\/A at 3\u00a0h after intraperitoneal BoNT\/A administration and complete neutralized 20\u2009\u00d7\u2009LD<jats:sub>50<\/jats:sub> of BoNT\/A at 0.5\u00a0h after intraperitoneal BoNT\/A administration. Thus, LUZ-A1-A3 is a promising agent for the pre-exposure prophylaxis and post-exposure treatment of BoNT\/A.<\/jats:p>","DOI":"10.1038\/s41598-023-48008-5","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T10:02:28Z","timestamp":1701079348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A human bispecific antibody neutralizes botulinum neurotoxin serotype A"],"prefix":"10.1038","volume":"13","author":[{"given":"Jiansheng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"48008_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/toxins11120686","volume":"11","author":"O Rossetto","year":"2019","unstructured":"Rossetto, O. & Montecucco, C. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins 11, 686. https:\/\/doi.org\/10.3390\/toxins11120686 (2019).","journal-title":"Toxins"},{"key":"48008_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1124\/pr.116.012658","volume":"69","author":"M Pirazzini","year":"2017","unstructured":"Pirazzini, M., Rossetto, O., Eleopra, R. & Montecucco, C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol. Rev. 69, 200\u2013235. https:\/\/doi.org\/10.1124\/pr.116.012658 (2017).","journal-title":"Pharmacol. Rev."},{"key":"48008_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/ijms20051181","volume":"20","author":"E Janik","year":"2019","unstructured":"Janik, E., Ceremuga, M., Saluk-Bijak, J. & Bijak, M. Biological toxins as the potential tools for bioterrorism. Int. J. Mol. Sci. 20, 1181. https:\/\/doi.org\/10.3390\/ijms20051181 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"48008_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40696-016-0017-4","volume":"2","author":"T Berger","year":"2016","unstructured":"Berger, T. et al. Toxins as biological weapons for terror-characteristics, challenges and medical countermeasures: A mini-review. Disaster Military Med. 2, 7. https:\/\/doi.org\/10.1186\/s40696-016-0017-4 (2016).","journal-title":"Disaster Military Med."},{"key":"48008_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/toxins10050190","volume":"10","author":"DA Tehran","year":"2018","unstructured":"Tehran, D. A. & Pirazzini, M. Novel botulinum neurotoxins: Exploring underneath the iceberg tip. Toxins 10, 190. https:\/\/doi.org\/10.3390\/toxins10050190 (2018).","journal-title":"Toxins"},{"key":"48008_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.toxicon.2015.09.011","volume":"107","author":"KK Hill","year":"2015","unstructured":"Hill, K. K., Xie, G., Foley, B. T. & Smith, T. J. Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon Off. J. Int. Soc. Toxinol. 107, 2\u20138. https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.011 (2015).","journal-title":"Toxicon Off. J. Int. Soc. Toxinol."},{"key":"48008_CR7","first-page":"182","volume":"229","author":"LL Simpson","year":"1984","unstructured":"Simpson, L. L. The binding fragment from tetanus toxin antagonizes the neuromuscular blocking actions of botulinum toxin. J. Pharmacol. Exp. Ther. 229, 182\u2013187 (1984).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"48008_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0006-8993(84)91136-3","volume":"305","author":"LL Simpson","year":"1984","unstructured":"Simpson, L. L. Botulinum toxin and tetanus toxin recognize similar membrane determinants. Brain Res. 305, 177\u2013180. https:\/\/doi.org\/10.1016\/0006-8993(84)91136-3 (1984).","journal-title":"Brain Res."},{"key":"48008_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/toxins10100421","volume":"10","author":"JR Davies","year":"2018","unstructured":"Davies, J. R., Liu, S. M. & Acharya, K. R. Variations in the botulinum neurotoxin binding domain and the potential for novel therapeutics. Toxins 10, 421. https:\/\/doi.org\/10.3390\/toxins10100421 (2018).","journal-title":"Toxins"},{"key":"48008_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","author":"SS Arnon","year":"2001","unstructured":"Arnon, S. S. et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285, 1059\u20131070. https:\/\/doi.org\/10.1001\/jama.285.8.1059 (2001).","journal-title":"JAMA"},{"key":"48008_CR11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/2338","volume":"5","author":"DB Lacy","year":"1998","unstructured":"Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R. & Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898\u2013902. https:\/\/doi.org\/10.1038\/2338 (1998).","journal-title":"Nat. Struct. Biol."},{"key":"48008_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/78005","volume":"7","author":"S Swaminathan","year":"2000","unstructured":"Swaminathan, S. & Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7, 693\u2013699. https:\/\/doi.org\/10.1038\/78005 (2000).","journal-title":"Nat. Struct. Biol."},{"key":"48008_CR13","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.vaccine.2020.02.060","volume":"38","author":"FJ Liu","year":"2020","unstructured":"Liu, F. J. et al. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A. Vaccine 38, 2978\u20132983. https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.060 (2020).","journal-title":"Vaccine"},{"key":"48008_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/toxins13010031","volume":"13","author":"DM Snow","year":"2021","unstructured":"Snow, D. M. et al. A monoclonal antibody combination against both serotypes A and B botulinum toxin prevents inhalational botulism in a guinea pig model. Toxins 13, 31. https:\/\/doi.org\/10.3390\/toxins13010031 (2021).","journal-title":"Toxins"},{"key":"48008_CR15","doi-asserted-by":"publisher","first-page":"e21540","DOI":"10.1096\/fj.202002492R","volume":"35","author":"S Brier","year":"2021","unstructured":"Brier, S. et al. Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A. FASEB J. 35, e21540. https:\/\/doi.org\/10.1096\/fj.202002492R (2021).","journal-title":"FASEB J."},{"key":"48008_CR16","doi-asserted-by":"publisher","first-page":"112871","DOI":"10.1016\/j.jim.2020.112871","volume":"487","author":"X Xiong","year":"2020","unstructured":"Xiong, X. et al. Production and characterization of a neutralizing antibody against botulinum neurotoxin A. J. Immunol. Methods 487, 112871. https:\/\/doi.org\/10.1016\/j.jim.2020.112871 (2020).","journal-title":"J. Immunol. Methods"},{"key":"48008_CR17","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1038\/s41598-017-07457-5","volume":"7","author":"G Yao","year":"2017","unstructured":"Yao, G. et al. A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding. Sci. Rep. 7, 7438. https:\/\/doi.org\/10.1038\/s41598-017-07457-5 (2017).","journal-title":"Sci. Rep."},{"key":"48008_CR18","doi-asserted-by":"publisher","first-page":"e13245","DOI":"10.1371\/journal.pone.0013245","volume":"5","author":"J Prigent","year":"2010","unstructured":"Prigent, J. et al. Production and characterisation of a neutralising chimeric antibody against botulinum neurotoxin A. PLoS ONE 5, e13245. https:\/\/doi.org\/10.1371\/journal.pone.0013245 (2010).","journal-title":"PLoS ONE"},{"key":"48008_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/toxins10020084","volume":"10","author":"J Lou","year":"2018","unstructured":"Lou, J. et al. A single tri-epitopic antibody virtually recapitulates the potency of a combination of three monoclonal antibodies in neutralization of botulinum neurotoxin serotype A. Toxins 10, 84. https:\/\/doi.org\/10.3390\/toxins10020084 (2018).","journal-title":"Toxins"},{"key":"48008_CR20","doi-asserted-by":"publisher","first-page":"e3023","DOI":"10.1371\/journal.pone.0003023","volume":"3","author":"SP Adekar","year":"2008","unstructured":"Adekar, S. P. et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 3, e3023. https:\/\/doi.org\/10.1371\/journal.pone.0003023 (2008).","journal-title":"PLoS ONE"},{"key":"48008_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/protein\/gzq001","volume":"23","author":"J Lou","year":"2010","unstructured":"Lou, J. et al. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng. Des. Sel. 23, 311\u2013319. https:\/\/doi.org\/10.1093\/protein\/gzq001 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"48008_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1472-6750-11-113","volume":"11","author":"S Chahboun","year":"2011","unstructured":"Chahboun, S. et al. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol. 11, 113. https:\/\/doi.org\/10.1186\/1472-6750-11-113 (2011).","journal-title":"BMC Biotechnol."},{"key":"48008_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jmb.2010.01.070","volume":"397","author":"J Dong","year":"2010","unstructured":"Dong, J. et al. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J. Mol. Biol. 397, 1106\u20131118. https:\/\/doi.org\/10.1016\/j.jmb.2010.01.070 (2010).","journal-title":"J. Mol. Biol."},{"key":"48008_CR24","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.vaccine.2009.02.051","volume":"27","author":"T Takahashi","year":"2009","unstructured":"Takahashi, T. et al. Localization of the sites and characterization of the mechanisms by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine 27, 2616\u20132624. https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.051 (2009).","journal-title":"Vaccine"},{"key":"48008_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/toxins13090641","volume":"13","author":"C Garcia-Rodriguez","year":"2021","unstructured":"Garcia-Rodriguez, C. et al. A four-monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotypes C and D. Toxins 13, 641. https:\/\/doi.org\/10.3390\/toxins13090641 (2021).","journal-title":"Toxins"},{"key":"48008_CR26","doi-asserted-by":"publisher","first-page":"e0174187","DOI":"10.1371\/journal.pone.0174187","volume":"12","author":"Y Fan","year":"2017","unstructured":"Fan, Y. et al. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes. PLoS ONE 12, e0174187. https:\/\/doi.org\/10.1371\/journal.pone.0174187 (2017).","journal-title":"PLoS ONE"},{"key":"48008_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011\u20131027. https:\/\/doi.org\/10.1200\/JCO.2005.06.081 (2005).","journal-title":"J. Clin. Oncol."},{"key":"48008_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","volume":"41","author":"LM Henricks","year":"2015","unstructured":"Henricks, L. M., Schellens, J. H., Huitema, A. D. & Beijnen, J. H. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat. Rev. 41, 859\u2013867. https:\/\/doi.org\/10.1016\/j.ctrv.2015.10.008 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"48008_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(14)71170-2 (2015).","journal-title":"Lancet Oncol."},{"key":"48008_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783 (2017).","journal-title":"N. Engl. J. Med."},{"key":"48008_CR31","doi-asserted-by":"publisher","first-page":"43331","DOI":"10.1074\/jbc.M112.397869","volume":"287","author":"BJ Wranik","year":"2012","unstructured":"Wranik, B. J. et al. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J. Biol. Chem. 287, 43331\u201343339. https:\/\/doi.org\/10.1074\/jbc.M112.397869 (2012).","journal-title":"J. Biol. Chem."},{"key":"48008_CR32","first-page":"154","volume":"1","author":"F Hajighasemi","year":"2004","unstructured":"Hajighasemi, F., Saboor-Yaraghi, A. & Shokri, F. Measurements of affinity constant of anti-human IgG monoclonal antibodies by an ELISA-based method. Irn J Immunol 1, 154\u2013161 (2004).","journal-title":"Irn J Immunol"},{"key":"48008_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/21645515.2019.1633878","volume":"16","author":"DY Shi","year":"2020","unstructured":"Shi, D. Y. et al. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E. Hum. Vaccin Immunother. 16, 100\u2013108. https:\/\/doi.org\/10.1080\/21645515.2019.1633878 (2020).","journal-title":"Hum. Vaccin Immunother."},{"key":"48008_CR34","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.biochi.2010.06.010","volume":"92","author":"YZ Yu","year":"2010","unstructured":"Yu, Y. Z. et al. Development and preclinical evaluation of a new F(ab\u2019)(2) antitoxin against botulinum neurotoxin serotype A. Biochimie 92, 1315\u20131320. https:\/\/doi.org\/10.1016\/j.biochi.2010.06.010 (2010).","journal-title":"Biochimie"},{"key":"48008_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.virol.2021.01.009","volume":"558","author":"R Wang","year":"2021","unstructured":"Wang, R., Lu, J., Chen, L., Yu, Y. & Yang, Z. A human bispecific neutralization antibody against four serotypes of dengue virus. Virology 558, 49\u201356. https:\/\/doi.org\/10.1016\/j.virol.2021.01.009 (2021).","journal-title":"Virology"},{"key":"48008_CR36","doi-asserted-by":"publisher","first-page":"11346","DOI":"10.1073\/pnas.172229899","volume":"99","author":"A Nowakowski","year":"2002","unstructured":"Nowakowski, A. et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99, 11346\u201311350. https:\/\/doi.org\/10.1073\/pnas.172229899 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"48008_CR37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7883\/yoken.65.138","volume":"65","author":"H Zhao","year":"2012","unstructured":"Zhao, H., Nakamura, K., Kohda, T., Mukamoto, M. & Kozaki, S. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Jpn. J. Infect. Dis. 65, 138\u2013145 (2012).","journal-title":"Jpn. J. Infect. Dis."},{"key":"48008_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/hyb.2007.0536","volume":"27","author":"SP Adekar","year":"2008","unstructured":"Adekar, S. P. et al. A human monoclonal antibody that binds serotype A botulinum neurotoxin. Hybridoma 27, 11\u201317. https:\/\/doi.org\/10.1089\/hyb.2007.0536 (2008).","journal-title":"Hybridoma"},{"key":"48008_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/hyb.2007.0549","volume":"27","author":"SP Adekar","year":"2008","unstructured":"Adekar, S. P. et al. A natural human IgM antibody that neutralizes botulinum neurotoxin in vivo. Hybridoma 27, 65\u201369. https:\/\/doi.org\/10.1089\/hyb.2007.0549 (2008).","journal-title":"Hybridoma"},{"key":"48008_CR40","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.celrep.2020.01.107","volume":"30","author":"KH Lam","year":"2020","unstructured":"Lam, K. H. et al. Structural insights into rational design of single-domain antibody-based antitoxins against botulinum neurotoxins. Cell Rep 30, 2526-2539 e2526. https:\/\/doi.org\/10.1016\/j.celrep.2020.01.107 (2020).","journal-title":"Cell Rep"},{"key":"48008_CR41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/toxins10030105","volume":"10","author":"C Garcia-Rodriguez","year":"2018","unstructured":"Garcia-Rodriguez, C. et al. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype E subtypes. Toxins 10, 105. https:\/\/doi.org\/10.3390\/toxins10030105 (2018).","journal-title":"Toxins"},{"key":"48008_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jmb.2005.06.003","volume":"351","author":"A Razai","year":"2005","unstructured":"Razai, A. et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J. Mol. Biol. 351, 158\u2013169. https:\/\/doi.org\/10.1016\/j.jmb.2005.06.003 (2005).","journal-title":"J. Mol. Biol."},{"key":"48008_CR43","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1124\/jpet.108.136242","volume":"326","author":"FH Al-Saleem","year":"2008","unstructured":"Al-Saleem, F. H. et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J. Pharmacol. Exp. Ther. 326, 856\u2013863. https:\/\/doi.org\/10.1124\/jpet.108.136242 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"48008_CR44","doi-asserted-by":"publisher","first-page":"e0139905","DOI":"10.1371\/journal.pone.0139905","volume":"10","author":"S Miethe","year":"2015","unstructured":"Miethe, S. et al. Development of human-like scFv-Fc neutralizing botulinum neurotoxin E. PLoS ONE 10, e0139905. https:\/\/doi.org\/10.1371\/journal.pone.0139905 (2015).","journal-title":"PLoS ONE"},{"key":"48008_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/protein\/gzq111","volume":"24","author":"C Garcia-Rodriguez","year":"2011","unstructured":"Garcia-Rodriguez, C. et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng. Des. Sel. PEDS 24, 321\u2013331. https:\/\/doi.org\/10.1093\/protein\/gzq111 (2011).","journal-title":"Protein Eng. Des. Sel. PEDS"},{"key":"48008_CR46","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/toxins11070407","volume":"11","author":"CS Bever","year":"2019","unstructured":"Bever, C. S., Scotcher, M., Cheng, L. W., Hnasko, R. M. & Stanker, L. H. Development and characterization of monoclonal antibodies to botulinum neurotoxin type E. Toxins 11, 407. https:\/\/doi.org\/10.3390\/toxins11070407 (2019).","journal-title":"Toxins"},{"key":"48008_CR47","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1128\/AEM.63.4.1214-1218.1997","volume":"63","author":"T Kubota","year":"1997","unstructured":"Kubota, T. et al. Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl. Environ. Microbiol. 63, 1214\u20131218. https:\/\/doi.org\/10.1128\/AEM.63.4.1214-1218.1997 (1997).","journal-title":"Appl. Environ. Microbiol."},{"key":"48008_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12033-013-9669-1","volume":"55","author":"H Bakherad","year":"2013","unstructured":"Bakherad, H. et al. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol. Biotechnol. 55, 159\u2013167. https:\/\/doi.org\/10.1007\/s12033-013-9669-1 (2013).","journal-title":"Mol. Biotechnol."},{"key":"48008_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/toxins14020135","volume":"14","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. Functional EL-HN fragment as a potent candidate vaccine for the prevention of botulinum neurotoxin serotype E. Toxins 14, 135. https:\/\/doi.org\/10.3390\/toxins14020135 (2022).","journal-title":"Toxins"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48008-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48008-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48008-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T22:01:46Z","timestamp":1701122506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-48008-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["48008"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-48008-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20806"}}